๋ ˆ๋น„๋ผ์„ธํƒ / Levetiracetam

์ •์˜

๋ ˆ๋น„๋ผ์„ธํƒ(Levetiracetam, Keppra/q-PAM)์€ ์‘๊ธ‰์‹ค์—์„œ ๋ฐœ์ž‘ ํ›„ ํ•ญ๊ฒฝ๋ จ์ œ loading ๋˜๋Š” ๊ฒฝ๋ จ์„ฑ status epilepticus์˜ 2์ฐจ ์•ฝ์ œ๋กœ ์‚ฌ์šฉ๋˜๋Š” ํ•ญ๊ฒฝ๋ จ์ œ๋‹ค.

์ž„์ƒ ํ•ต์‹ฌ

๋‹จ์ˆœ seizure/cluster๊ฐ€ ๋ฉŽ์—ˆ๊ณ  postictal ์ƒํƒœ์—์„œ AED loading ๋ชฉ์ ์ด๋ฉด 20 mg/kg IV๊ฐ€ ํ”ํžˆ ์‚ฌ์šฉ๋œ๋‹ค. ๋ณ‘์› ํ”„๋กœํ† ์ฝœ์— ๋”ฐ๋ผ 30โ€“40 mg/kg๊นŒ์ง€ ์‚ฌ์šฉํ•˜๋Š” ๊ฒฝ์šฐ๋„ ์žˆ๋‹ค. BZD ํ›„์—๋„ ๊ฒฝ๋ จ์ด ์ง€์†๋˜๋Š” established convulsive status epilepticus์—์„œ๋Š” ๊ทผ๊ฑฐ ๊ธฐ๋ฐ˜ ์šฉ๋Ÿ‰์ด ๋” ๋†’๋‹ค. ESETT trial์—์„œ๋Š” levetiracetam 60 mg/kg IV, ์ตœ๋Œ€ 4.5 g ์šฉ๋Ÿ‰์„ ์‚ฌ์šฉํ–ˆ๋‹ค.

์ง„๋‹จ

์šฉ๋Ÿ‰ ์„ ํƒ์€ ํ˜„์žฌ ๋ฐœ์ž‘์ด ๋ฉŽ์—ˆ๋Š”์ง€, ongoing convulsion์ธ์ง€, benzodiazepine-refractory established SE์ธ์ง€์— ๋”ฐ๋ผ ๋‹ฌ๋ผ์ง„๋‹ค.

์น˜๋ฃŒ

50 kg: 20 mg/kg์€ 1 g, 60 mg/kg์€ 3 g์ด๋‹ค. 70 kg: 20 mg/kg์€ 1.4 g, 60 mg/kg์€ 4.2 g์ด๋‹ค. 80 kg ์ด์ƒ์—์„œ๋Š” 60 mg/kg ํˆฌ์—ฌ ์‹œ ์ตœ๋Œ€ 4.5 g ์ œํ•œ์— ๊ฑธ๋ฆด ์ˆ˜ ์žˆ๋‹ค.

์ถœ์ฒ˜

AES convulsive SE guideline 2016; ESETT NEJM 2019.

๐ŸŒฑ ์ถœ์ฒ˜ raw


๋ณธ ๋ฌธ์„œ๋Š” ํ•™์Šตยท์ฐธ๊ณ ์šฉ์ด๋ฉฐ ์‹ค์ œ ์ง„๋ฃŒ ๊ฒฐ์ •์€ ์ž„์ƒ์˜์˜ ํŒ๋‹จ์ž…๋‹ˆ๋‹ค.

๐Ÿ“ ์ถ”๊ฐ€ (2026-05-15, source: 2026-05-15-1155-ae63fd91-q2.md)

์ •์˜

Levetiracetam์€ benzodiazepine ํˆฌ์—ฌ ํ›„์—๋„ ์ง€์†๋˜๋Š” convulsive status epilepticus์—์„œ ์‚ฌ์šฉํ•  ์ˆ˜ ์žˆ๋Š” 2์ฐจ ํ•ญ๊ฒฝ๋ จ์ œ ์ค‘ ํ•˜๋‚˜์ด๋‹ค.

์ž„์ƒ ํ•ต์‹ฌ

์‘๊ธ‰ loading ์šฉ๋Ÿ‰์€ 60 mg/kg IV, ์ตœ๋Œ€ 4.5 g์ด๋‹ค. ๋ณดํ†ต ์•ฝ 10๋ถ„ ์ •๋„์— ๊ฑธ์ณ infusionํ•œ๋‹ค. ์‹ ๊ธฐ๋Šฅ์— ๋”ฐ๋ฅธ ์šฉ๋Ÿ‰ ์กฐ์ ˆ์€ ์ฃผ๋กœ maintenance์—์„œ ๊ณ ๋ คํ•˜๋ฉฐ, ์‘๊ธ‰ loading์€ ๋ณดํ†ต ์ง€์—ฐํ•˜์ง€ ์•Š๋Š”๋‹ค. ์ถฉ๋ถ„ํ•œ benzodiazepine ํˆฌ์—ฌ ํ›„ seizure๊ฐ€ ์ง€์†๋˜๋ฉด fosphenytoin, valproate, levetiracetam ์ค‘ ํ•˜๋‚˜๋ฅผ 2nd-line์œผ๋กœ ์„ ํƒํ•œ๋‹ค.

์ง„๋‹จ

์ด ์•ฝ์ œ ์„ ํƒ์€ benzodiazepine-refractory convulsive status epilepticus ์ƒํ™ฉ์—์„œ ๊ณ ๋ ค๋œ๋‹ค.

์น˜๋ฃŒ

Levetiracetam 60 mg/kg IV, max 4500 mg loading. ์ดํ›„์—๋„ ๋ฐœ์ž‘์ด ์ง€์†๋˜๋ฉด refractory status epilepticus๋กœ ๋ณด๊ณ  intubation, continuous sedation, ICU pathway๋ฅผ ๊ณ ๋ คํ•œ๋‹ค.

์ถœ์ฒ˜

ESETT trial์—์„œ levetiracetam 60 mg/kg max 4500 mg์„ ์‚ฌ์šฉํ–ˆ๊ณ  fosphenytoin/valproate์™€ efficacyยทsafety๊ฐ€ ์œ ์‚ฌํ–ˆ๋‹ค. AES CSE guideline์€ benzodiazepine ์ดˆ๊ธฐ์น˜๋ฃŒ ํ›„ second therapy phase๋ฅผ ๊ถŒ๊ณ ํ•œ๋‹ค.

๐Ÿ“ ์ถ”๊ฐ€ (2026-06-02, source: 2026-06-02-1420-6d64fd7b.md)

์ •์˜

Levetiracetam์€ benzodiazepine ํˆฌ์—ฌ ํ›„์—๋„ ์ง€์†๋˜๋Š” convulsive status epilepticus์—์„œ ์‚ฌ์šฉํ•  ์ˆ˜ ์žˆ๋Š” 2์ฐจ ํ•ญ๊ฒฝ๋ จ์ œ์ด๋‹ค. Raw ์ž๋ฃŒ์—์„œ๋Š” q-PAM์„ levetiracetam์œผ๋กœ ๊ฐ€์ •ํ•˜์˜€๋‹ค.

์ž„์ƒ ํ•ต์‹ฌ

BZD๋ฅผ ์ถฉ๋ถ„ํžˆ ์‚ฌ์šฉํ–ˆ๋Š”๋ฐ๋„ ์ „์‹  ๊ฒฝ๋ จ์ด ์ง€์† ๋˜๋Š” ์žฌ๋ฐœํ•˜๋ฉด IV loading์„ ๊ณ ๋ คํ•œ๋‹ค. ๊ถŒ์žฅ loading dose๋Š” 60 mg/kg IV, ์ตœ๋Œ€ 4,500 mg์ด๋‹ค. ๋ณดํ†ต 10โ€“15๋ถ„์— ๊ฑธ์ณ infusionํ•œ๋‹ค. Renal failure๊ฐ€ ์žˆ์–ด๋„ ์‘๊ธ‰ loading์€ ๋จผ์ € ์‹œํ–‰ํ•˜๊ณ , ์ดํ›„ maintenance dose์—์„œ renal adjustment๋ฅผ ๊ณ ๋ คํ•œ๋‹ค.

์ง„๋‹จ

๋Œ€์ƒ ์ƒํ™ฉ์€ 1์ฐจ benzodiazepine ์น˜๋ฃŒ ํ›„์—๋„ ์กฐ์ ˆ๋˜์ง€ ์•Š๋Š” convulsive status epilepticus์ด๋‹ค.

์น˜๋ฃŒ

Lorazepam ๋“ฑ BZD ํ›„ ์ง€์†๋˜๋Š” ๋ฐœ์ž‘์—์„œ levetiracetam 60 mg/kg IV load๋ฅผ ์‚ฌ์šฉํ•œ๋‹ค. ๊ณ„์† ์ง€์†๋˜๋ฉด refractory status epilepticus pathway๋กœ ์ง„ํ–‰ํ•œ๋‹ค.

์ถœ์ฒ˜

ESETT NEJM 2019; DailyMed levetiracetam injection.